1916 related articles for article (PubMed ID: 30622344)
1. Delivery technologies for cancer immunotherapy.
Riley RS; June CH; Langer R; Mitchell MJ
Nat Rev Drug Discov; 2019 Mar; 18(3):175-196. PubMed ID: 30622344
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.
Mukalel AJ; Riley RS; Zhang R; Mitchell MJ
Cancer Lett; 2019 Aug; 458():102-112. PubMed ID: 31100411
[TBL] [Abstract][Full Text] [Related]
3. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
[TBL] [Abstract][Full Text] [Related]
4. Delivering safer immunotherapies for cancer.
Milling L; Zhang Y; Irvine DJ
Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
[TBL] [Abstract][Full Text] [Related]
5. Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics.
Zhou L; Zou M; Xu Y; Lin P; Lei C; Xia X
Front Oncol; 2022; 12():864301. PubMed ID: 35664731
[TBL] [Abstract][Full Text] [Related]
6. Nano-immunotherapy: Overcoming tumour immune evasion.
Guevara ML; Persano F; Persano S
Semin Cancer Biol; 2021 Feb; 69():238-248. PubMed ID: 31883449
[TBL] [Abstract][Full Text] [Related]
7. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology Approaches to Improving Cancer Immunotherapy.
Hagan CT; Medik YB; Wang AZ
Adv Cancer Res; 2018; 139():35-56. PubMed ID: 29941106
[TBL] [Abstract][Full Text] [Related]
9. Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus.
Huang M; Chen W; Wang M; Huang Y; Liu H; Ming Y; Chen Y; Tang Z; Jia B
BioDrugs; 2023 May; 37(3):331-352. PubMed ID: 37178431
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles in cancer immunotherapies: An innovative strategy.
Nasirmoghadas P; Mousakhani A; Behzad F; Beheshtkhoo N; Hassanzadeh A; Nikoo M; Mehrabi M; Kouhbanani MAJ
Biotechnol Prog; 2021 Mar; 37(2):e3070. PubMed ID: 32829506
[TBL] [Abstract][Full Text] [Related]
11. Particle-mediated delivery of cytokines for immunotherapy.
Christian DA; Hunter CA
Immunotherapy; 2012 Apr; 4(4):425-41. PubMed ID: 22512636
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.
Caster JM; Callaghan C; Seyedin SN; Henderson K; Sun B; Wang AZ
Adv Drug Deliv Rev; 2019 Apr; 144():3-15. PubMed ID: 31330165
[TBL] [Abstract][Full Text] [Related]
13. Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System.
Muluh TA; Chen Z; Li Y; Xiong K; Jin J; Fu S; Wu J
Int J Nanomedicine; 2021; 16():2389-2404. PubMed ID: 33790556
[TBL] [Abstract][Full Text] [Related]
14. Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy.
Han S; Huang K; Gu Z; Wu J
Nanoscale; 2020 Jan; 12(2):413-436. PubMed ID: 31829394
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle mediated cancer immunotherapy.
Gupta J; Safdari HA; Hoque M
Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
[TBL] [Abstract][Full Text] [Related]
16. The potential of nanoparticle vaccines as a treatment for cancer.
Urbanavicius D; Alvarez T; Such GK; Johnston APR; Mintern JD
Mol Immunol; 2018 Jun; 98():2-7. PubMed ID: 29395251
[TBL] [Abstract][Full Text] [Related]
17. Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics.
Hong E; Dobrovolskaia MA
Adv Drug Deliv Rev; 2019 Feb; 141():3-22. PubMed ID: 29339144
[TBL] [Abstract][Full Text] [Related]
18. Gold nanoparticle mediated cancer immunotherapy.
Almeida JP; Figueroa ER; Drezek RA
Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
Bucktrout SL; Bluestone JA; Ramsdell F
Genome Med; 2018 Oct; 10(1):79. PubMed ID: 30376867
[TBL] [Abstract][Full Text] [Related]
20. Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona.
Mikelez-Alonso I; Aires A; Cortajarena AL
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
